ATE169500T1 - Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen - Google Patents

Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen

Info

Publication number: ATE169500T1
Authority: AT; Austria
Prior art keywords: guanosine; treatment; production; medicinal products; cerebral function
Prior art date: 1992-06-24

Application number

AT93913178T

Other languages

English (en)

Inventor

Marie A Peeters

Jerome Lejeune

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-24

Filing date

1993-06-23

Publication date

1998-08-15

1993-06-23 Application filed by Pf Medicament filed Critical Pf Medicament

1998-08-15 Application granted granted Critical

1998-08-15 Publication of ATE169500T1 publication Critical patent/ATE169500T1/de

Links

NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 title abstract 4
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 title abstract 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 title abstract 2
229940029575 guanosine Drugs 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title abstract 2
230000002490 cerebral effect Effects 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000011580 syndromic disease Diseases 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
201000010374 Down Syndrome Diseases 0.000 abstract 1
208000001914 Fragile X syndrome Diseases 0.000 abstract 1
201000006347 Intellectual Disability Diseases 0.000 abstract 1
208000036626 Mental retardation Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000003542 behavioural effect Effects 0.000 abstract 1
230000005978 brain dysfunction Effects 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000002759 chromosomal effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
208000013403 hyperactivity Diseases 0.000 abstract 1
230000035874 hyperreactivity Effects 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AT93913178T 1992-06-24 1993-06-23 Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen ATE169500T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9207721A FR2692784B1 (fr)	1992-06-24	1992-06-24	Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.

Publications (1)

Publication Number	Publication Date
ATE169500T1 true ATE169500T1 (de)	1998-08-15

Family

ID=9431118

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93913178T ATE169500T1 (de)	1992-06-24	1993-06-23	Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen

Country Status (7)

Country	Link
EP (1)	EP0646009B1 (de)
AT (1)	ATE169500T1 (de)
AU (1)	AU4333893A (de)
DE (1)	DE69320349D1 (de)
DK (1)	DK0646009T3 (de)
FR (1)	FR2692784B1 (de)
WO (1)	WO1994000132A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996003125A1 (en) *	1994-07-25	1996-02-08	Glasky Alvin J	Carbon monoxide dependent guanylyl cyclase modifiers
US6440455B1 (en) *	1997-09-02	2002-08-27	Children's Medical Center Corporation	Methods for modulating the axonal outgrowth of central nervous system neurons
US20020045580A1 (en) *	1999-11-24	2002-04-18	Sacks Meir S.	Compositions for raising uric acid levels and methods of using same
EP1100507B1 (de) *	1998-07-31	2007-01-24	Sacks, Meir S.	Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
US6365593B2 (en)	2000-04-12	2002-04-02	Repligen Corporation	Methylxanthines in the diagnosis and treatment of autistic disorder
US7172871B1 (en)	2000-09-07	2007-02-06	Children's Medical Center Corporation	Methods and compositions for modulating axonal outgrowth of central nervous system neurons
AU2003264195A1 (en) *	2002-09-03	2004-03-29	Neurological Technologies Inc.	Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
US8912144B2 (en)	2003-12-16	2014-12-16	Children's Medical Center Corporation	Method for treating stroke via administration of NEP1-40 and inosine
US20120058099A1 (en) *	2009-03-04	2012-03-08	Children's Medical Center Corporation	Use of hypoxanthine for promotion of neuronal outgrowth
JP2015030673A (ja) *	2013-07-31	2015-02-16	奥野製薬工業株式会社	アミロイドベータペプチド阻害剤
CN111973615A (zh) *	2019-05-22	2020-11-24	华东理工大学	一种治疗躁狂型精神障碍及精神分裂症的药物
US20250057890A1 (en) *	2022-01-07	2025-02-20	Maruhachi Muramatsu, Inc.	Functional food containing bonito-derived extract for preventing or ameliorating neuropsychiatric disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR5084E (fr) *	1905-06-23	1905-12-11	Etienne Auguste Marie Faure	Système d'aération continue ou alternative
JPS41137Y1 (de) *	1964-04-23	1966-01-07
JPS41136Y1 (de) *	1965-04-09	1966-01-07
FR2437834A1 (fr) *	1978-10-04	1980-04-30	Lejeune Jerome	Compositions pharmaceutiques a base de l-serine ou de glycine
JPS61277619A (ja) *	1985-06-04	1986-12-08	Otsuka Pharmaceut Factory Inc	肝疾患治療剤
DE3701497A1 (de) *	1987-01-20	1988-07-28	Frankhof Wolfgang	Arzneimittel, enthaltend lokalanaesthetika und nukleoside sowie dessen verwendung zur behandlung von muskelverletzungen
EP0355899B1 (de) *	1988-08-16	1994-11-02	Nippon Shinyaku Company, Limited	Nucleotid-Derivate
FR2665636B1 (fr) *	1990-08-10	1994-10-07	Adir	Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.

1992
- 1992-06-24 FR FR9207721A patent/FR2692784B1/fr not_active Expired - Fee Related
1993
- 1993-06-23 DE DE69320349T patent/DE69320349D1/de not_active Expired - Lifetime
- 1993-06-23 AT AT93913178T patent/ATE169500T1/de not_active IP Right Cessation
- 1993-06-23 DK DK93913178T patent/DK0646009T3/da active
- 1993-06-23 WO PCT/FR1993/000625 patent/WO1994000132A1/fr not_active Ceased
- 1993-06-23 AU AU43338/93A patent/AU4333893A/en not_active Abandoned
- 1993-06-23 EP EP93913178A patent/EP0646009B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
FR2692784B1 (fr)	1995-06-30
WO1994000132A1 (fr)	1994-01-06
DK0646009T3 (da)	1999-05-17
EP0646009B1 (de)	1998-08-12
AU4333893A (en)	1994-01-24
FR2692784A1 (fr)	1993-12-31
EP0646009A1 (de)	1995-04-05
DE69320349D1 (de)	1998-09-17

Similar Documents

Publication	Publication Date	Title
ATE209492T1 (de)	2001-12-15	Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
ATE349425T1 (de)	2007-01-15	Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
ATE97809T1 (de)	1993-12-15	Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe und wirksam in der therapie organisch mentaler stoerungen sowie die entsprechenden arzneimittel.
NL300406I1 (nl)	2009-11-02	Gesubstitueerde dihydrodibenzo (d,f)azepinen, werkwijze ter bereiding ervan, hun toepassing bij het behandelen van enkele verstoringen van het centraal zenuwsysteem, en farmaceutische samenstellingen die ze bevatten
MX25502A (es)	1993-10-01	PROCEDIMIENTO PARA LA PRODUCCION DE 2-METIL-10-(4-METIL-1-PIPERAZINIL)-4H-TIENO(2,3-b)(1,5)BENZODIAZEPINA Y PRODUCTO OBTENIDO.
ATE142877T1 (de)	1996-10-15	Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
ATE271874T1 (de)	2004-08-15	Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
ATE300296T1 (de)	2005-08-15	Hochreines ethyleicosapentaenat und andere epa- derivate zur behandlung von neurologischen erkrankungen
DE69428130D1 (de)	2001-10-04	Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
ATE229806T1 (de)	2003-01-15	Wirkstoff zur behandlung neurodegenerativer störungen
ATE169500T1 (de)	1998-08-15	Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen
ZA934550B (en)	1994-01-27	Derivatives in the vitamin D series with modifications in 20-position, process for their production,intermediate products for this process,pharmaceutical prepartions containing these derivatives as well as their use for the production of pharmaceutical agents
DE69126039D1 (de)	1997-06-12	Wirkstoff zur haarmodifikation und haarpflegeprodukt, die beide einen antikeratin-antikörper enthalten, und herstellung des antikeratin-antikörpers
ATE269077T1 (de)	2004-07-15	Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE249828T1 (de)	2003-10-15	Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
RU93051352A (ru)	1996-07-20	Замещенные производные циклогексана, способ их получения и применение соединений для лечения заболеваний
TW197423B (de)	1993-01-01
DE3583220D1 (de)	1991-07-18	Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
DE69130679D1 (de)	1999-02-04	Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
EP0383171A3 (de)	1991-07-24	2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen
DE3787437D1 (de)	1993-10-21	Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.
ATE402253T1 (de)	2008-08-15	Humane adulte astrozyten, sowie deren herstellung und verwendung
DE59010302D1 (de)	1996-05-30	R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
DE3885022D1 (de)	1993-11-25	Thiosulfinsäurederivate, und die Verwendung von Thiosulfinsäurederivaten zur Herstellung von Arzneimitteln für die Behandlung von Entzündungserkrankungen.
ATE112276T1 (de)	1994-10-15	Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.

Legal Events

Date	Code	Title	Description
1999-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties